Francesco Ramirez

Prof. Francesco Ramirez


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
JCJason R. Cook
Jason R. Cook
NCNicholas P. Clayton
Nicholas P. Clayton
LCLuca Carta
Luca Carta
JGJosephine Galatioto
Josephine Galatioto
ECEmily Chiu
Emily Chiu
FRFrancesco Ramirez
Francesco Ramirez
Objective—: Studies of mice with mild Marfan syndrome (MFS) have correlated the development of thoracic aortic aneurysm (TAA) with improper stimulation of noncanonical (Erk-mediated) TGFβ signaling by the angiotensin type I receptor (AT1r). This correlation was largely based on comparable TAA modifications by either systemic TGFβ neutralization or AT1r antagonism. However, subsequent investigations have called into question some key aspects of this mechanism of arterial disease in MFS. To resolve these controversial points, here we made a head-to-head comparison of the therapeutic benefits of TGFβ neutralization and AT1r antagonism in mice with progressively severe MFS ( Fbn1 mgR/mgR mice). Approach and Results—: Aneurysm growth, media degeneration, aortic levels of phosphorylated Erk and Smad proteins and the average survival of Fbn1 mgR/mgR mice were compared after a ≈3-month-long treatment with placebo and either the AT1r antagonist losartan or the TGFβ-neutralizing antibody 1D11. In contrast to the beneficial effect of losartan, TGFβ neutralization either exacerbated or mitigated TAA formation depending on whether treatment was initiated before (postnatal day 16; P16) or after (P45) aneurysm formation, respectively. Biochemical evidence-related aneurysm growth with Erk-mediated AT1r signaling, and medial degeneration with TGFβ hyperactivity that was in part AT1r dependent. Importantly, P16-initiated treatment with losartan combined with P45-initiated administration of 1D11 prevented death of Fbn1 mgR/mgR mice from ruptured TAA. Conclusions—: By demonstrating that promiscuous AT1r and TGFβ drive partially overlapping processes of arterial disease in MFS mice, our study argues for a therapeutic strategy against TAA that targets both signaling pathways although sparing the early protective role of TGFβ.

10 June 2009 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
FRFrancesco Ramirez
Francesco Ramirez
LSLynn Y. Sakai
Lynn Y. Sakai

20 September 2010 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
HNHarikiran Nistala
Harikiran Nistala
SLSui Lee-Arteaga
Sui Lee-Arteaga
SSSilvia Smaldone
Silvia Smaldone
GSGabriella Siciliano
Gabriella Siciliano
LCLuca Carta
Luca Carta
FRFrancesco Ramirez
Francesco Ramirez
Extracellular regulation of signaling by transforming growth factor (TGF)–β family members is emerging as a key aspect of organ formation and tissue remodeling. In this study, we demonstrate that fibrillin-1 and -2, the structural components of extracellular microfibrils, differentially regulate TGF-β and bone morphogenetic protein (BMP) bioavailability in bone. Fibrillin-2–null (Fbn2−/−) mice display a low bone mass phenotype that is associated with reduced bone formation in vivo and impaired osteoblast maturation in vitro. This Fbn2−/− phenotype is accounted for by improper activation of latent TGF-β that selectively blunts expression of osterix, the transcriptional regulator of osteoblast maturation, and collagen I, the structural template for bone mineralization. Cultured osteoblasts from Fbn1−/− mice exhibit improper latent TGF-β activation as well, but mature faster because of increased availability of otherwise matrix-bound BMPs. Additional in vitro evidence excludes a direct role of microfibrils in supporting mineral deposition. Together, these findings identify the extracellular microfibrils as critical regulators of bone formation through the modulation of endogenous TGF-β and BMP signaling.

8 March 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
FCFrank S. Cikach
Frank S. Cikach
CKChristopher D. Koch
Christopher D. Koch
TMTimothy J. Mead
Timothy J. Mead
JGJosephine Galatioto
Josephine Galatioto
BWBelinda B. Willard
Belinda B. Willard
SASuneel S. Apte
Suneel S. Apte
Proteoglycan accumulation is a hallmark of medial degeneration in thoracic aortic aneurysm and dissection (TAAD). Here, we defined the aortic proteoglycanome using mass spectrometry, and based on the findings, investigated the large aggregating proteoglycans aggrecan and versican in human ascending TAAD and a mouse model of severe Marfan syndrome. The aortic proteoglycanome comprises 20 proteoglycans including aggrecan and versican. Antibodies against these proteoglycans intensely stained medial degeneration lesions in TAAD, contrasting with modest intralamellar staining in controls. Aggrecan, but not versican, was increased in longitudinal analysis of Fbn1 mgR/mgR aortas. TAAD and Fbn1 mgR/mgR aortas had increased aggrecan and versican mRNAs, and reduced expression of a key proteoglycanase gene, ADAMTS5 , was seen in TAAD. Fbn1 mgR/mgR mice with ascending aortic dissection and/or rupture had dramatically increased aggrecan staining compared with mice without these complications. Thus, aggrecan and versican accumulation in ascending TAAD occurs via increased synthesis and/or reduced proteolytic turnover, and correlates with aortic dissection/rupture in Fbn1 mgR/mgR mice. Tissue swelling imposed by aggrecan and versican is proposed to be profoundly deleterious to aortic wall mechanics and smooth muscle cell homeostasis, predisposing to type-A dissections. These proteoglycans provide potential biomarkers for refined risk stratification and timing of elective aortic aneurysm repair.

1 October 2018 in Matrix Biology
Verified
Journal Article
Closed access
FRFrancesco Ramirez
Francesco Ramirez
CCCristina Caescu
Cristina Caescu
EWElisabeth Wondimu
Elisabeth Wondimu
JGJosephine Galatioto
Josephine Galatioto

17 February 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JCJason R. Cook
Jason R. Cook
LCLuca Carta
Luca Carta
LBLudovic Bénard
Ludovic Bénard
ECElie R. Chemaly
Elie R. Chemaly
ECEmily Chiu
Emily Chiu
FRFrancesco Ramirez
Francesco Ramirez
Patients with Marfan syndrome (MFS), a multisystem disorder caused by mutations in the gene encoding the extracellular matrix (ECM) protein fibrillin 1, are unusually vulnerable to stress-induced cardiac dysfunction. The prevailing view is that MFS-associated cardiac dysfunction is the result of aortic and/or valvular disease. Here, we determined that dilated cardiomyopathy (DCM) in fibrillin 1–deficient mice is a primary manifestation resulting from ECM-induced abnormal mechanosignaling by cardiomyocytes. MFS mice displayed spontaneous emergence of an enlarged and dysfunctional heart, altered physical properties of myocardial tissue, and biochemical evidence of chronic mechanical stress, including increased angiotensin II type I receptor (AT1R) signaling and abated focal adhesion kinase (FAK) activity. Partial fibrillin 1 gene inactivation in cardiomyocytes was sufficient to precipitate DCM in otherwise phenotypically normal mice. Consistent with abnormal mechanosignaling, normal cardiac size and function were restored in MFS mice treated with an AT1R antagonist and in MFS mice lacking AT1R or β-arrestin 2, but not in MFS mice treated with an angiotensin-converting enzyme inhibitor or lacking angiotensinogen. Conversely, DCM associated with abnormal AT1R and FAK signaling was the sole abnormality in mice that were haploinsufficient for both fibrillin 1 and β1 integrin. Collectively, these findings implicate fibrillin 1 in the physiological adaptation of cardiac muscle to elevated workload.